Joel B Epstein1,2, Sara Gharapetian3, Ali R Rejali3, Rachel Zabner3, Michael Lill4,3,5, Dimitrios Tzachanis5. 1. Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA. joel.epstein@cshs.org. 2. Cedars-Sinai Health System, Los Angeles, CA, USA. joel.epstein@cshs.org. 3. Cedars-Sinai Health System, Los Angeles, CA, USA. 4. Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA. 5. Blood and Marrow Transplant Program, University of California, San Diego, San Diego, CA, USA.
Abstract
PURPOSE: Herpes simplex virus (HSV) infection commonly occurs during the immunosuppression associated with hematopoietic stem cell transplantation (HSCT). Prophylaxis of recurrent infection and management of clinical infection have relied upon acyclovir and congeners. More recently, resistant HSV infection is seen in HSCT and presents new challenges in management. We present a case of HSV following HSCT that provided effective symptomatic management. RESULTS: Oral symptoms and lesions were repeatedly reduced when topical cidofovir was used, strongly supporting the effect of cidofovir used in a host who could not tolerate systemic antiviral medications. CONCLUSIONS: Topical cidofovir can provide effective management of symptomatic oropharyngeal HSV while reducing risk of systemic toxicity and drug interaction and represents an additional approach to management for management in medically compromised patients.
PURPOSE: Herpes simplex virus (HSV) infection commonly occurs during the immunosuppression associated with hematopoietic stem cell transplantation (HSCT). Prophylaxis of recurrent infection and management of clinical infection have relied upon acyclovir and congeners. More recently, resistant HSV infection is seen in HSCT and presents new challenges in management. We present a case of HSV following HSCT that provided effective symptomatic management. RESULTS: Oral symptoms and lesions were repeatedly reduced when topical cidofovir was used, strongly supporting the effect of cidofovir used in a host who could not tolerate systemic antiviral medications. CONCLUSIONS: Topical cidofovir can provide effective management of symptomatic oropharyngeal HSV while reducing risk of systemic toxicity and drug interaction and represents an additional approach to management for management in medically compromised patients.
Authors: Y Chen; C Scieux; V Garrait; G Socié; V Rocha; J M Molina; D Thouvenot; F Morfin; L Hocqueloux; L Garderet; H Espérou; F Sélimi; A Devergie; G Leleu; M Aymard; F Morinet; E Gluckman; P Ribaud Journal: Clin Infect Dis Date: 2000-10-10 Impact factor: 9.079
Authors: M T van der Beek; A M G A Laheij; J E Raber-Durlacher; P A von dem Borne; R Wolterbeek; C S van der Blij-de Brouwer; C van Loveren; E C J Claas; A C M Kroes; J J de Soet; A C T M Vossen Journal: Bone Marrow Transplant Date: 2012-02-13 Impact factor: 5.483
Authors: Ila M Saunders; Amit Lahoti; Roy F Chemaly; Cynthia Trevino; Michael Westmoreland; Chitra Hosing Journal: J Oncol Pharm Pract Date: 2014-12-07 Impact factor: 1.809
Authors: Jun Hu; John C Krauss; Micheline Moyal-Barracco; Laraine L Washer; Hope K Haefner; Ebony Parker-Featherstone Journal: Int J Womens Dermatol Date: 2021-06-20